Go back to the Europarl portal

Choisissez la langue de votre document :

  • bg - български
  • es - español
  • cs - čeština
  • da - dansk
  • de - Deutsch
  • et - eesti keel
  • el - ελληνικά
  • en - English (Selected)
  • fr - français
  • ga - Gaeilge
  • hr - hrvatski
  • it - italiano
  • lv - latviešu valoda
  • lt - lietuvių kalba
  • hu - magyar
  • mt - Malti
  • nl - Nederlands
  • pl - polski
  • pt - português
  • ro - română
  • sk - slovenčina
  • sl - slovenščina
  • fi - suomi
  • sv - svenska
Parliamentary questions
PDF 0kWORD 0k
16 April 2018
E-000830/2018(ASW)
Reply
Question reference: E-000830/2018

In order to support the work done by Member States in the field of rare diseases, the Council has adopted a recommendation on an action in the field of rare diseases(1), in which it recommends Member States to take action with regard to such diseases.

Furthermore, in its Conclusions on Encouraging Member States-driven Voluntary Cooperation between Health Systems of 16 June 2017, the Council noted that tackling the specific characteristics and challenges arising in the healthcare market for therapeutic innovations, in particular in the field of rare diseases, may benefit from voluntary cooperation so as to ensure a balance between access, quality, affordability and sustainability of health systems(2).

(1)OJ C 151, 3.7.2009, p. 7.
(2)OJ C 206, 30.6.2017, p. 3.

Last updated: 18 April 2018Legal notice